{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:31:10Z","timestamp":1791361870514,"version":"4.3.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,11,14]],"date-time":"2014-11-14T00:00:00Z","timestamp":1415923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,11,14]],"date-time":"2014-11-14T00:00:00Z","timestamp":1415923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1038\/leu.2014.326","type":"journal-article","created":{"date-parts":[[2014,11,14]],"date-time":"2014-11-14T07:36:17Z","timestamp":1415950577000},"page":"1104-1114","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["PF-114, a potent and selective inhibitor of native and mutated BCR\/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation"],"prefix":"10.1038","volume":"29","author":[{"given":"A A","family":"Mian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Rafiei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Haberbosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Zeifman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Titov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Stroylov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Metodieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Stroganov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Novikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Brill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Chilov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Hoelzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O G","family":"Ottmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Ruthardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,14]]},"reference":[{"key":"BFleu2014326_CR1","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","volume":"116","author":"TP Hughes","year":"2010","unstructured":"Hughes TP, Hochhaus A, Branford S, Muller MC, Kaeda JS, Foroni L et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010; 116: 3758\u20133765.","journal-title":"Blood"},{"key":"BFleu2014326_CR2","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1182\/blood-2013-04-495598","volume":"122","author":"M Hoglund","year":"2013","unstructured":"Hoglund M, Sandin F, Hellstrom K, Bjoreman M, Bjorkholm M, Brune M et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood 2013; 122: 1284\u20131292.","journal-title":"Blood"},{"key":"BFleu2014326_CR3","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","volume":"99","author":"M Talpaz","year":"2002","unstructured":"Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928\u20131937.","journal-title":"Blood"},{"key":"BFleu2014326_CR4","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/leu.2011.355","volume":"26","author":"FJ Giles","year":"2012","unstructured":"Giles FJ, Kantarjian HM, le Coutre PD, Baccarani M, Mahon FX, Blakesley RE et al. Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia 2012; 26: 959\u2013962.","journal-title":"Leukemia"},{"key":"BFleu2014326_CR5","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1038\/leu.2012.324","volume":"27","author":"OG Ottmann","year":"2013","unstructured":"Ottmann OG, Larson RA, Kantarjian HM, le Coutre PD, Baccarani M, Hochhaus A et al. Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome\u2014positive acute lymphoblastic leukemia. Leukemia 2013; 27: 1411\u20131413.","journal-title":"Leukemia"},{"key":"BFleu2014326_CR6","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408\u20132417.","journal-title":"N Engl J Med"},{"key":"BFleu2014326_CR7","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O'Brien","year":"2003","unstructured":"O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994\u20131004.","journal-title":"N Engl J Med"},{"key":"BFleu2014326_CR8","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3324\/haematol.11248","volume":"92","author":"S Soverini","year":"2007","unstructured":"Soverini S, Iacobucci I, Baccarani M, Martinelli G . Targeted therapy and the T315I mutation in Philadelphia-positive leukemias. Haematologica 2007; 92: 437\u2013439.","journal-title":"Haematologica"},{"key":"BFleu2014326_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/MOH.0b013e32834399ef","volume":"18","author":"S Branford","year":"2011","unstructured":"Branford S, Hughes TP . Mutational analysis in chronic myeloid leukemia: when and what to do? Curr Opin Hematol 2011; 18: 111\u2013116.","journal-title":"Curr Opin Hematol"},{"key":"BFleu2014326_CR10","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1182\/blood-2006-11-052373","volume":"110","author":"H Pfeifer","year":"2007","unstructured":"Pfeifer H, Wassmann B, Pavlova A, Wunderle L, Oldenburg J, Binckebanck A et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2007; 110: 727\u2013734.","journal-title":"Blood"},{"key":"BFleu2014326_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","volume":"2","author":"NP Shah","year":"2002","unstructured":"Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117\u2013125.","journal-title":"Cancer Cell"},{"key":"BFleu2014326_CR12","doi-asserted-by":"publisher","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","volume":"12","author":"S Soverini","year":"2006","unstructured":"Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006; 12: 7374\u20137379.","journal-title":"Clin Cancer Res"},{"key":"BFleu2014326_CR13","doi-asserted-by":"publisher","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","volume":"27","author":"T Hughes","year":"2009","unstructured":"Hughes T, Saglio G, Branford S, Soverini S, Kim DW, Muller MC et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009; 27: 4204\u20134210.","journal-title":"J Clin Oncol"},{"key":"BFleu2014326_CR14","doi-asserted-by":"publisher","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","volume":"114","author":"MC Muller","year":"2009","unstructured":"Muller MC, Cortes JE, Kim DW, Druker BJ, Erben P, Pasquini R et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 2009; 114: 4944\u20134953.","journal-title":"Blood"},{"key":"BFleu2014326_CR15","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2009.25.4896","volume":"28","author":"JE Cortes","year":"2010","unstructured":"Cortes JE, Jones D, O'Brien S, Jabbour E, Konopleva M, Ferrajoli A et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 2010; 28: 392\u2013397.","journal-title":"J Clin Oncol"},{"key":"BFleu2014326_CR16","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1200\/JCO.2009.25.4920","volume":"28","author":"JE Cortes","year":"2010","unstructured":"Cortes JE, Jones D, O'Brien S, Jabbour E, Ravandi F, Koller C et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010; 28: 398\u2013404.","journal-title":"J Clin Oncol"},{"key":"BFleu2014326_CR17","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","volume":"30","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kim DW, Kantarjian HM, Brummendorf TH, Dyagil I, Griskevicius L et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012; 30: 3486\u20133492.","journal-title":"J Clin Oncol"},{"key":"BFleu2014326_CR18","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260\u20132270.","journal-title":"N Engl J Med"},{"key":"BFleu2014326_CR19","doi-asserted-by":"publisher","first-page":"4933","DOI":"10.1182\/blood-2009-07-232595","volume":"114","author":"G Rosti","year":"2009","unstructured":"Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G et al. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood 2009; 114: 4933\u20134938.","journal-title":"Blood"},{"key":"BFleu2014326_CR20","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251\u20132259.","journal-title":"N Engl J Med"},{"key":"BFleu2014326_CR21","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","volume":"110","author":"J Cortes","year":"2007","unstructured":"Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O'Brien S et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 2007; 110: 4005\u20134011.","journal-title":"Blood"},{"key":"BFleu2014326_CR22","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007; 110: 3540\u20133546.","journal-title":"Blood"},{"key":"BFleu2014326_CR23","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1172\/JCI30890","volume":"117","author":"NP Shah","year":"2007","unstructured":"Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 2007; 117: 2562\u20132569.","journal-title":"J Clin Invest"},{"key":"BFleu2014326_CR24","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/sj.leu.2404236","volume":"20","author":"FE Nicolini","year":"2006","unstructured":"Nicolini FE, Corm S, Le QH, Sorel N, Hayette S, Bories D et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia 2006; 20: 1061\u20131066.","journal-title":"Leukemia"},{"key":"BFleu2014326_CR25","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.3324\/haematol.11369","volume":"92","author":"FE Nicolini","year":"2007","unstructured":"Nicolini FE, Hayette S, Corm S, Bachy E, Bories D, Tulliez M et al. Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation. Haematologica 2007; 92: 1238\u20131241.","journal-title":"Haematologica"},{"key":"BFleu2014326_CR26","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O'Hare","year":"2009","unstructured":"O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009; 16: 401\u2013412.","journal-title":"Cancer Cell"},{"key":"BFleu2014326_CR27","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","volume":"367","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012; 367: 2075\u20132088.","journal-title":"N Engl J Med"},{"key":"BFleu2014326_CR28","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013; 369: 1783\u20131796.","journal-title":"N Engl J Med"},{"key":"BFleu2014326_CR29","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","volume":"109","author":"FJ Giles","year":"2007","unstructured":"Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ . MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007; 109: 500\u2013502.","journal-title":"Blood"},{"key":"BFleu2014326_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/leu.2012.181","volume":"27","author":"FJ Giles","year":"2013","unstructured":"Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 2013; 27: 107\u2013112.","journal-title":"Leukemia"},{"key":"BFleu2014326_CR31","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1182\/blood-2009-03-211466","volume":"116","author":"R Tanaka","year":"2010","unstructured":"Tanaka R, Squires MS, Kimura S, Yokota A, Nagao R, Yamauchi T et al. Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells. Blood 2010; 116: 2089\u20132095.","journal-title":"Blood"},{"key":"BFleu2014326_CR32","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/nrc2147","volume":"7","author":"JV Melo","year":"2007","unstructured":"Melo JV, Barnes DJ . Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007; 7: 441\u2013453.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"BFleu2014326_CR33","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1182\/asheducation-2005.1.118","volume":"2005","author":"O. G. Ottmann","year":"2005","unstructured":"Ottmann OG, Wassmann B . Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2005, 118\u2013122.","journal-title":"Hematology"},{"key":"BFleu2014326_CR34","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1158\/1078-0432.CCR-09-3314","volume":"17","author":"T O'Hare","year":"2011","unstructured":"O'Hare T, Deininger MW, Eide CA, Clackson T, Druker BJ . Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clin Cancer Res 2011; 17: 212\u2013221.","journal-title":"Clin Cancer Res"},{"key":"BFleu2014326_CR35","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/leu.2012.5","volume":"26","author":"H Pfeifer","year":"2012","unstructured":"Pfeifer H, Lange T, Wystub S, Wassmann B, Maier J, Binckebanck A et al. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia. Leukemia 2012; 26: 1475\u20131481.","journal-title":"Leukemia"},{"key":"BFleu2014326_CR36","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1182\/blood-2005-06-2209","volume":"106","author":"S Kimura","year":"2005","unstructured":"Kimura S, Naito H, Segawa H, Kuroda J, Yuasa T, Sato K et al. NS-187, a potent and selective dual Bcr-Abl\/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005; 106: 3948\u20133954.","journal-title":"Blood"},{"key":"BFleu2014326_CR37","doi-asserted-by":"publisher","first-page":"400","DOI":"10.4161\/cc.4.3.1560","volume":"4","author":"N von Bubnoff","year":"2005","unstructured":"von Bubnoff N, Barwisch S, Speicher MR, Peschel C, Duyster J . A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: implications for clinical resistance in targeted cancer treatment. Cell Cycle 2005; 4: 400\u2013406.","journal-title":"Cell Cycle"},{"key":"BFleu2014326_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1747-0285.2010.01054.x","volume":"77","author":"T Zhou","year":"2011","unstructured":"Zhou T, Commodore L, Huang WS, Wang Y, Thomas M, Keats J et al. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des 2011; 77: 1\u201311.","journal-title":"Chem Biol Drug Des"},{"key":"BFleu2014326_CR39","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1021\/jm101479y","volume":"54","author":"AE Gould","year":"2011","unstructured":"Gould AE, Adams R, Adhikari S, Aertgeerts K, Afroze R, Blackburn C et al. Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors. J Med Chem 2011; 54: 1836\u20131846.","journal-title":"J Med Chem"},{"key":"BFleu2014326_CR40","doi-asserted-by":"publisher","first-page":"7260","DOI":"10.1016\/j.bmc.2010.08.017","volume":"18","author":"Y Oguro","year":"2010","unstructured":"Oguro Y, Miyamoto N, Okada K, Takagi T, Iwata H, Awazu Y et al. Design, synthesis, and evaluation of 5-methyl-4-phenoxy-5H-pyrrolo[3,2-d]pyrimidine derivatives: novel VEGFR2 kinase inhibitors binding to inactive kinase conformation. Bioorg Med Chem 2010; 18: 7260\u20137273.","journal-title":"Bioorg Med Chem"},{"key":"BFleu2014326_CR41","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1002\/prot.23099","volume":"79","author":"OV Stroganov","year":"2011","unstructured":"Stroganov OV, Novikov FN, Zeifman AA, Stroylov VS, Chilov GG . TSAR, a new graph-theoretical approach to computational modeling of protein side-chain flexibility: modeling of ionization properties of proteins. Proteins 2011; 79: 2693\u20132710.","journal-title":"Proteins"},{"key":"BFleu2014326_CR42","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1021\/ci800166p","volume":"48","author":"OV Stroganov","year":"2008","unstructured":"Stroganov OV, Novikov FN, Stroylov VS, Kulkov V, Chilov GG . Lead finder: an approach to improve accuracy of protein-ligand docking, binding energy estimation, and virtual screening. J Chem Inf Model 2008; 48: 2371\u20132385.","journal-title":"J Chem Inf Model"},{"key":"BFleu2014326_CR43","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/bioinformatics\/btt055","volume":"29","author":"S Pronk","year":"2013","unstructured":"Pronk S, Pall S, Schulz R, Larsson P, Bjelkmar P, Apostolov R et al. GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics 2013; 29: 845\u2013854.","journal-title":"Bioinformatics"},{"key":"BFleu2014326_CR44","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/1756-0500-5-367","volume":"5","author":"AW Sousa da Silva","year":"2012","unstructured":"Sousa da Silva AW, Vranken WF . ACPYPE - AnteChamber PYthon Parser interfacE. BMC Res Notes 2012; 5: 367.","journal-title":"BMC Res Notes"},{"key":"BFleu2014326_CR45","doi-asserted-by":"publisher","first-page":"e80070","DOI":"10.1371\/journal.pone.0080070","volume":"8","author":"S Badura","year":"2013","unstructured":"Badura S, Tesanovic T, Pfeifer H, Wystub S, Nijmeijer BA, Liebermann M et al. Differential effects of selective inhibitors targeting the PI3K\/AKT\/mTOR pathway in acute lymphoblastic leukemia. PLoS One 2013; 8: e80070.","journal-title":"PLoS One"},{"key":"BFleu2014326_CR46","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1038\/leu.2009.194","volume":"23","author":"AA Mian","year":"2009","unstructured":"Mian AA, Oancea C, Zhao Z, Ottmann OG, Ruthardt M . Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR\/ABL. Leukemia 2009; 23: 2242\u20132247.","journal-title":"Leukemia"},{"key":"BFleu2014326_CR47","first-page":"1521","volume":"34","author":"X Zheng","year":"2009","unstructured":"Zheng X, Oancea C, Henschler R, Ruthardt M . Cooperation between constitutively activated c-Kit signaling and leukemogenic transcription factors in the determination of the leukemic phenotype in murine hematopoietic stem cells. Int J Oncol 2009; 34: 1521\u20131531.","journal-title":"Int J Oncol"},{"key":"BFleu2014326_CR48","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1182\/blood-2003-03-0811","volume":"102","author":"T Beissert","year":"2003","unstructured":"Beissert T, Puccetti E, Bianchini A, Guller S, Boehrer S, Hoelzer D et al. Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571. Blood 2003; 102: 2985\u20132993.","journal-title":"Blood"},{"key":"BFleu2014326_CR49","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","volume":"16","author":"A Hochhaus","year":"2002","unstructured":"Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190\u20132196.","journal-title":"Leukemia"},{"key":"BFleu2014326_CR50","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"NP Shah","year":"2004","unstructured":"Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL . Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399\u2013401.","journal-title":"Science"},{"key":"BFleu2014326_CR51","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.bbapap.2009.11.008","volume":"1804","author":"PW Manley","year":"2010","unstructured":"Manley PW, Drueckes P, Fendrich G, Furet P, Liebetanz J, Martiny-Baron G et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 2010; 1804: 445\u2013453.","journal-title":"Biochim Biophys Acta"},{"key":"BFleu2014326_CR52","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122: 872\u2013884.","journal-title":"Blood"},{"key":"BFleu2014326_CR53","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.exphem.2008.11.002","volume":"37","author":"BA Nijmeijer","year":"2009","unstructured":"Nijmeijer BA, Szuhai K, Goselink HM, van Schie ML, van der Burg M, de Jong D et al. Long-term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors. Exp Hematol 2009; 37: 376\u2013385.","journal-title":"Exp Hematol"},{"key":"BFleu2014326_CR54","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1084\/jem.189.9.1399","volume":"189","author":"S Li","year":"1999","unstructured":"Li S, Ilaria RL Jr., Million RP, Daley GQ, Van Etten RA . The P190, P210, and P230 forms of the BCR\/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 1999; 189: 1399\u20131412.","journal-title":"J Exp Med"},{"key":"BFleu2014326_CR55","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/1471-2407-12-411","volume":"12","author":"AA Mian","year":"2012","unstructured":"Mian AA, Metodieva A, Badura S, Khateb M, Ruimi N, Najajreh Y et al. Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I. BMC Cancer 2012; 12: 411.","journal-title":"BMC Cancer"},{"key":"BFleu2014326_CR56","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","volume":"108","author":"HA Bradeen","year":"2006","unstructured":"Bradeen HA, Eide CA, O'Hare T, Johnson KJ, Willis SG, Lee FY et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006; 108: 2332\u20132338.","journal-title":"Blood"},{"key":"BFleu2014326_CR57","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","volume":"125","author":"D Montani","year":"2012","unstructured":"Montani D, Bergot E, Gunther S, Savale L, Bergeron A, Bourdin A et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125: 2128\u20132137.","journal-title":"Circulation"},{"key":"BFleu2014326_CR58","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/cncr.25079","volume":"116","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, le Coutre P, Cortes J, Pinilla-Ibarz J, Nagler A, Hochhaus A et al. Phase 1 study of INNO-406, a dual Abl\/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. Cancer 2010; 116: 2665\u20132672.","journal-title":"Cancer"},{"key":"BFleu2014326_CR59","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1093\/jnci\/djr292","volume":"103","author":"P Le Coutre","year":"2011","unstructured":"Le Coutre P, Rea D, Abruzzese E, Dombret H, Trawinska MM, Herndlhofer S et al. Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst 2011; 103: 1347\u20131348.","journal-title":"J Natl Cancer Inst"},{"key":"BFleu2014326_CR60","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1073\/pnas.0409770102","volume":"102","author":"MR Burgess","year":"2005","unstructured":"Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL . Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci USA 2005; 102: 3395\u20133400.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2014326.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2014326","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2014326.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T23:57:19Z","timestamp":1717545439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2014326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,14]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["BFleu2014326"],"URL":"https:\/\/doi.org\/10.1038\/leu.2014.326","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,14]]},"assertion":[{"value":"16 July 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The entire study was financed by Fusion Pharma LLC, Moscow, Russia. AZ, IT, VS, OS and GC are employees of Fusion Pharma. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}